Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 11/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.34 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.34 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | CLK3 | P49761 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21154507 | 0.91 | PTPN11 (0.46) | PTPN11EGFRKCNH2LRRK2 | |
| SCHEMBL25514515 | 0.88 | PTPN11 (0.41) | PTPN11EGFRKCNH2BRD4MTOR | |
| SCHEMBL25514526 | 0.85 | PTPN11 (0.41) | PTPN11EGFRKCNH2BRD4MTOR | |
| SCHEMBL25514750 | 0.81 | PTPN11 (0.45) | PTPN11EGFRKCNH2MTORPIK3CA | |
| SCHEMBL25514639 | 0.81 | PTPN11 (0.44) | PTPN11EGFRKCNH2 | |
| SCHEMBL25514669 | 0.80 | PTPN11 (0.43) | PTPN11EGFRKCNH2LRRK2 | |
| SCHEMBL23186778 | 0.79 | PTPN11 (0.44) | PTPN11EGFRKCNH2 | |
| SCHEMBL25514717 | 0.77 | PTPN11 (0.43) | PTPN11EGFRKCNH2PIK3CA | |
| SCHEMBL23186799 | 0.76 | PTPN11 (0.44) | PTPN11EGFRKCNH2 | |
| SCHEMBL25514652 | 0.76 | PTPN11 (0.40) | PTPN11EGFRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN22, PTPN2 | PTPN11 8/4885EGFR 2069/4885KCNH2 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.